Shares of Heron Therapeutics Inc. (NASDAQ:HRTX) fell 5% during mid-day trading on Wednesday . The company traded as low as $18.25 and last traded at $18.25, with a volume of 230,221 shares changing hands. The stock had previously closed at $19.21.

A number of research firms have recently issued reports on HRTX. Cantor Fitzgerald reiterated a “buy” rating on shares of Heron Therapeutics in a report on Sunday, May 8th. Cowen and Company restated a “buy” rating on shares of Heron Therapeutics in a report on Saturday, July 9th. Leerink Swann set a $33.00 target price on shares of Heron Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 11th. Zacks Investment Research upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, Brean Capital restated a “buy” rating and set a $55.00 target price on shares of Heron Therapeutics in a report on Saturday, August 13th. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $47.70.

The company’s 50-day moving average is $18.69 and its 200-day moving average is $18.85.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Monday, August 8th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.96) by $0.21. Analysts anticipate that Heron Therapeutics Inc. will post ($4.39) earnings per share for the current year.

In related news, insider Robert Rosen sold 100,000 shares of the stock in a transaction on Wednesday, August 10th. The stock was sold at an average price of $23.30, for a total value of $2,330,000.00. Following the transaction, the insider now directly owns 102,640 shares in the company, valued at approximately $2,391,512. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.